Clinical Evaluation of a Test for Monitoring Patients Diagnosed With Chronic Myeloid Leukemia (CML)

Cepheid

Status: Completed

Conditions: Leukemia, Myelogenous, Chronic

Treatments: Device: Xpert BCR-ABL Ultra

Study type: Observational

Funder types: Industry

Identifiers

NCT03421626

231

Details and patient eligibility

About

The objective of this study is to establish the performance of an assay that detects mRNA transcript levels in patients diagnosed with CML. The study is conducted at locations within the United States. Testing is performed on peripheral blood specimens provided by eligible enrolled patients. Results from this study will not be used for patient management decisions.

Enrollment: 266 patients

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• prospective specimens:

  • Patient is at least 18 years of age
  • Patient has provided documented informed consent as required by the reviewing IRB. Experimental Bill of Rights will also be documented for all subjects enrolled in applicable states.
  • Patient has been diagnosed with CML.
  • Patient consents to provide at least 12 mL of peripheral blood for study purposes

• frozen specimens:

  • Specimen is from a subject diagnosed with CML
  • Specimen meets the manufacturer's criteria to support testing by both diagnostic assays

Exclusion criteria

• prospective specimens:

  • Patient is considered to be of insufficient health to supply the required volume of peripheral blood by his/her health care provider
  • Patient has been previously enrolled

• frozen specimens: • Specimen previously enrolled

Trial design

266 participants in 1 patient group

Primary Enrollment

Description:

Initial enrollment of patients with history of CML

Treatment:

Device: Xpert BCR-ABL Ultra